Sermorelin Acetate

Sermorelin acetate is a synthetic peptide analog of growth hormone–releasing hormone (GHRH). It has been used in certain diagnostic tests and therapeutic contexts related to growth hormone deficiency.

In more recent years, sermorelin has also appeared in wellness and age-related discussions, often in ways that extend beyond its original evidence base and labeled indications.

Sermorelin mimics endogenous GHRH and acts at the pituitary to stimulate physiologic, pulsatile secretion of growth hormone. In contrast to direct GH administration, it works upstream in the GH axis and relies on intact hypothalamic–pituitary function.

Downstream effects occur through the same general GH/IGF-1 pathways as endogenous hormone, with magnitude and pattern depending on baseline GH status and other regulatory inputs.

Sermorelin has been used in specific diagnostic or therapeutic settings for growth hormone deficiency, particularly in children, with details depending on jurisdiction and era of practice. Over time, practice patterns have evolved, and other agents may be preferred in many contemporary guidelines.

Outside regulated indications, sermorelin is sometimes marketed for generalized "anti-aging" or wellness purposes. These uses often lack the same level of evidentiary support and may not align with local regulatory standards.

Sermorelin appears by name on the WADA Prohibited List, in the first bullet of sub-section S2.2.4, "Growth hormone releasing factors." It sits alongside CJC-1293, CJC-1295 and tesamorelin as a named example of a GHRH analogue. Two further bullets in the same sub-section capture growth hormone secretagogues such as ipamorelin and ibutamoren, and the GH-releasing peptides such as GHRP-2. All S2 substances are non-Specified Substances, so the default first-violation sanction is four years.

A prescription is not a therapeutic use exemption. This is the specific trap for sermorelin. Because it is dispensed through wellness, longevity and hormone-optimization clinics in some jurisdictions, an athlete can hold a genuine prescription and still commit an anti-doping rule violation: a TUE is granted by an anti-doping organization, not by a prescriber, and it requires a documented diagnosis for which no permitted alternative exists, and USADA notes that "any TUE application submitted to USADA without medical documentation will be returned to the athlete and will not be processed" (USADA, therapeutic use exemptions). Generalized "anti-aging," sleep, recovery or body-composition indications do not meet that bar. Diagnosed growth hormone deficiency is a different situation, but it is assessed through the TUE process, in advance, on endocrine evidence.

Detection: the honest picture. Sermorelin is a named target analyte in several validated doping-control methods, but the class has a documented enforcement gap that most peptide pages gloss over. Memdouh and colleagues put it plainly: although "there is evidence of their use, based on admissions and intelligence," GHRH analogues "do not appear to have been found in anti-doping samples by WADA accredited laboratories," which the authors attribute to "their small concentration in urine and limited knowledge about their metabolism" (Memdouh et al., Drug Test Anal 2021). That paper closed part of the gap by identifying nineteen in vitro metabolites and synthesising them as reference materials, alongside the known sermorelin metabolite sermorelin(3-29)-NH₂, to reach detection limits "generally 1 ng/ml (WADA required performance limit) or less."

Two other validated approaches exist. An immunoaffinity LC-HRMS/MS plasma assay covering sermorelin, CJC-1293, CJC-1295 and tesamorelin reported a "lower limit of detection (<50 pg/mL)" (Knoop et al., Anal Bioanal Chem 2016), and a 2026 nano-LC-Orbitrap urine method validated to WADA guidelines achieved "LODs (≤ 0.5 ng/mL)" for GHRH and its analogues, noting that urine analysis is hard because of the peptides' "inherent in vivo instability, rapid renal clearance, and low urinary concentrations" (Uçaktürk and Nemutlu, J Pharm Biomed Anal 2026).

The practical reading is not "undetectable." Validated methods exist and their sensitivity has improved with each of these publications, and anti-doping organizations routinely store samples for later re-analysis as methods advance. A detection gap that is actively closing is a poor thing to plan around.

Reported side effects include injection-site reactions, flushing, headache, and transient changes in GH/IGF-1–related markers. As with other interventions on the GH axis, there is theoretical concern about long-term impacts on glucose metabolism and tissue growth, particularly when used outside established indications.

Risk–benefit assessment and monitoring strategies should be individualized and guided by clinicians familiar with both GH physiology and current guidelines.

Sermorelin (GRF 1-29) is a truncated GHRH analog used to stimulate natural GH production. It relies on a functioning pituitary gland.

This information summarizes commonly discussed research and clinical practices.

Sermorelin acetate typically appears as a lyophilized powder for reconstitution. It has also existed as a licensed pharmaceutical, in two strengths and for two different purposes: Geref at 0.05 mg per ampoule (NDA 019863, approved December 1990) as a GHRH stimulation test, and Geref at 0.5 mg and 1 mg per vial (NDA 020443, approved September 1997, orphan designation) for paediatric treatment (Drugs@FDA). Both are discontinued, each carrying a Federal Register determination that the product was not withdrawn for safety or effectiveness reasons.

In current non-clinical use it is most often paired with a ghrelin-receptor agonist such as ipamorelin or GHRP-2. The two act at different receptors and their effects on GH release are synergistic rather than additive (Bowers et al., J Clin Endocrinol Metab 2004), which is the pharmacological reason such combinations exist. The specific compounded blends on the market have not been evaluated in a controlled trial.

Research on sermorelin has addressed its role in GH deficiency diagnosis and treatment, particularly in pediatric populations. Outcomes include GH stimulation responses, growth metrics, and safety endpoints.

More speculative uses, such as generalized "anti-aging" applications, have a thinner and more heterogeneous evidence base. Careful review of study design and alignment with modern guidelines is important when interpreting these findings.

For deeper dives on this peptide, see:

• Sermorelin Acetate benefits and areas of interest
• Sermorelin Acetate side effects and safety context
• Sermorelin Acetate dosing concepts (educational)
• Sermorelin Acetate research and evidence overview

Was sermorelin ever FDA-approved? Yes — the only compound in this family that was. FDA approved Geref (sermorelin acetate) under NDA 019863 in December 1990 as a diagnostic product and under NDA 020443 in September 1997, with orphan designation, for treatment. FDA's own 2024 summary notes that among growth hormone secretagogues, "only sermorelin (Geref, NDA 020443) was approved for the treatment of short stature associated with GHD in pediatric patients" (FDA briefing document, PCAC October 2024).

Why was it discontinued? Not for safety. Both Geref products are recorded in Drugs@FDA as discontinued with a Federal Register determination that the product "was not discontinued or withdrawn for safety or effectiveness reasons" (Drugs@FDA, NDA 020443). A contemporaneous review put it plainly: sermorelin "could not compete with rhGH and was withdrawn as a therapeutic entity by the manufacturer" (Walker, Clin Interv Aging 2006).

How does it compare to growth hormone itself? Directly, and it loses. In nine children with radiation-induced GH deficiency, GHRH(1-29)-NH₂ at 15 µg/kg twice daily raised height velocity from 3.3 to 6.0 cm/year over a year; switching the same children to growth hormone the following year produced 7.5 cm/year (Ogilvy-Stuart et al., Clin Endocrinol 1997). Two injections a day for a smaller effect is a losing commercial position, not a safety failure.

Does it work for everyone? No, and the old label said so. Geref's approval covered a preselected subpopulation of children with idiopathic GH deficiency who first passed a Geref stimulation test, with the instruction that children whose peak GH was below 2 ng/mL "should be excluded from Geref therapy." A secretagogue asks the pituitary to release growth hormone; if the pituitary cannot, no dose helps.

Does sermorelin improve sleep? The study most often cited for its anti-aging claims found the opposite on that specific endpoint. In 19 adults aged 55–71 given a closely related GHRH(1-29) analog at 10 µg/kg nightly for 16 weeks, IGF-1 rose within two weeks, skin thickness increased in both sexes and lean body mass increased in men — but sleep was unaffected in both groups (Khorram et al., J Clin Endocrinol Metab 1997).

How long does it last in the body? Sermorelin is GHRH(1-29) with no stabilising modifications, and its plasma half-life in humans is about 10 to 20 minutes, limited mainly by renal ultrafiltration and enzymatic degradation at the N-terminus (Esposito et al., Adv Drug Deliv Rev 2003). That number is why modified GRF 1-29 and CJC-1295 with DAC exist.